Compound traditional Chinese medicine composition for adjuvant therapy of cerebral hemorrhage combined with pulmonary infection and application of compound traditional Chinese medicine composition

Abstract

The invention discloses a compound traditional Chinese medicine composition for adjuvant therapy of cerebral hemorrhage combined with pulmonary infection. The compound traditional Chinese medicine composition is prepared from the following components in parts by weight: 30-60 parts of ephedra, 90-120 parts of gypsum, 30-50 parts of almond, 150-180 parts of raw astragalus membranaceus, 100-120 parts of radix stephaniae tetrandrae, 90-120 parts of ginseng, 60-80 parts of radix bupleuri, 40-60 parts of fructus aurantii, 20-40 parts of platycodon grandiflorum, 150-180 parts of honey-fried licorice root, 45-80 parts of mint and 3-4 parts of borneol. The compound traditional Chinese medicine composition disclosed by the invention can be prepared into a dosage form of spray, and compared with traditional decoction for oral administration, the compound traditional Chinese medicine composition is convenient to use and less in liquid intake, and meanwhile, gastrointestinal reaction and vomiting are avoided, and the risk of secondary aspiration is reduced.

Description

Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a compound Chinese medicine composition for assisting in the treatment of cerebral hemorrhage combined with lung infection and its application. Background Art

[0002] Intracerebral hemorrhage is a common cerebrovascular disease with an acute onset and rapid onset. Under various triggering factors, it can rapidly lead to cerebral edema, hematoma, and extensive neurological deficits. Pulmonary infection is a common complication of intracerebral hemorrhage. This is because intracerebral hemorrhage often leads to neurological impairment, impaired consciousness, and decreased swallowing and cough reflexes, making it difficult to expel respiratory secretions. Furthermore, patients with intracerebral hemorrhage are often older, have multiple underlying medical conditions, and have weakened immune systems. Treatment often involves invasive procedures such as nasogastric feeding tubes and mechanical ventilation, significantly increasing the risk of stroke-related pulmonary infection. Pulmonary infection secondary to intracerebral hemorrhage not only complicates treatment but is also a contributing factor to mortality. The medical community believes that stroke-related pulmonary infection requires aggressive treatment to minimize the infectious cause and mitigate the pathological effects of the pathogenic bacteria on tissues. Western medicine typically uses anti-infective and symptomatic supportive treatment, but this is ineffective. Prolonged bed rest can lead to persistent pulmonary infection, the development of resistance to multiple antibiotics, elevated inflammatory markers, nutritional depletion, and electrolyte imbalances, resulting in a severely adverse prognosis. Traditional Chinese Medicine (TCM) is an integral part of modern medicine. Through its principle of syndrome differentiation and treatment, combined with the Four Diagnostics, it offers unique advantages in the treatment of stroke-related pulmonary infections. Using TCM as an adjunctive treatment for stroke-related pulmonary infections improves clinical efficacy, is highly safe, and has no significant side effects. However, because patients with cerebral hemorrhage often experience varying degrees of impaired consciousness and dysphagia, they typically rely on nasogastric tubes for feeding. Traditional Chinese herbal decoctions are difficult to administer and can easily cause gastrointestinal reactions and vomiting, which can also affect fluid intake. Summary of the Invention

[0003] The purpose of the present invention is to provide a compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage complicated with lung infection.

[0004] Another object of the present invention is to provide a use of the compound Chinese medicine composition in preparing a medicine for auxiliary treatment of cerebral hemorrhage combined with lung infection.

[0005] In order to achieve the above object, the technical solution adopted by the present invention is as follows:

[0006] The first aspect of the present invention provides a compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection, which is prepared from the following components in parts by weight: 30-60 parts of ephedra, 90-120 parts of gypsum, 30-50 parts of apricot kernel, 150-180 parts of raw astragalus, 100-120 parts of tetrandra, 90-120 parts of ginseng, 60-80 parts of bupleurum, 40-60 parts of fructus aurantii, 20-40 parts of platycodon, 150-180 parts of roasted licorice, 45-80 parts of mint, and 3-4 parts of borneol.

[0007] Most preferably, the compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight:

[0008] 60 parts of Ephedra, 90 parts of Gypsum, 30 parts of Apricot Kernel, 150 parts of Astragalus, 100 parts of Stephania Tetrandra, 120 parts of Ginseng, 60 parts of Bupleurum, 40 parts of Fructus Aurantii Immaturus, 20 parts of Platycodon, 150 parts of Radix Glycyrrhizae Preparata, 80 parts of Menthol, and 3 parts of Borneolum Syntheticum.

[0009] Most preferably, the compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is made of the following components in parts by weight:

[0010] 45 parts of ephedra, 100 parts of gypsum, 40 parts of apricot kernel, 180 parts of raw astragalus, 100 parts of tetrandra, 120 parts of ginseng, 60 parts of bupleurum, 50 parts of fructus aurantii, 30 parts of platycodon, 150 parts of roasted liquorice, 60 parts of mint, and 3 parts of borneol.

[0011] Most preferably, the compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is made of the following components in parts by weight:

[0012] 30 parts of ephedra, 120 parts of gypsum, 50 parts of apricot kernel, 180 parts of raw astragalus, 120 parts of tetrandra, 90 parts of ginseng, 80 parts of bupleurum, 60 parts of fructus aurantii, 40 parts of platycodon, 180 parts of roasted liquorice, 45 parts of mint, 4 parts of borneol.

[0013] Most preferably, the compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is made of the following components in parts by weight:

[0014] 45 parts of ephedra, 105 parts of gypsum, 40 parts of apricot kernel, 165 parts of raw astragalus, 110 parts of tetrandra, 105 parts of ginseng, 70 parts of bupleurum, 50 parts of fructus aurantii, 30 parts of platycodon, 165 parts of roasted liquorice, 65 parts of mint, and 3.5 parts of borneol.

[0015] Most preferably, the compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is made of the following components in parts by weight:

[0016] 50 parts of ephedra, 110 parts of gypsum, 45 parts of apricot kernel, 170 parts of raw astragalus, 105 parts of tetrandra, 100 parts of ginseng, 65 parts of bupleurum, 45 parts of fructus aurantii, 35 parts of platycodon, 170 parts of roasted liquorice, 55 parts of mint, and 3 parts of borneol.

[0017] The second aspect of the present invention provides a use of the compound Chinese medicine composition in preparing a medicament for auxiliary treatment of cerebral hemorrhage complicated with lung infection.

[0018] The third aspect of the present invention provides a pharmaceutical preparation, which is prepared from the compound Chinese medicine composition and pharmaceutically acceptable excipients.

[0019] The dosage form of the pharmaceutical preparation is selected from sprays, capsules, tablets, powders, granules, oral liquids, pills and the like.

[0020] The pharmaceutically acceptable excipient is selected from at least one of a filler, a propellant, an emulsifier, a co-solvent, a stabilizer, a pH regulator, a disintegrant, a binder, a flavoring agent, a lubricant, a preservative, and a matrix.

[0021] A fourth aspect of the present invention provides a use of a pharmaceutical preparation in the preparation of a drug for the auxiliary treatment of cerebral hemorrhage combined with pulmonary infection.

[0022] The properties, flavor, meridians and functions of the Chinese medicinal raw materials of the present invention are as follows:

[0023] Ephedra: It tastes pungent, slightly bitter and warm in nature. It enters the lung and bladder meridians, induces sweating and relieves exterior symptoms, promotes lung function and relieves asthma, and promotes diuresis and reduces swelling.

[0024] Almond: bitter in taste, enters the lung meridian, relieves cough and asthma, and moistens the intestines and promotes bowel movements.

[0025] Gypsum: sweet, spicy and cold in nature, enters the lung and stomach meridians, clears away heat and detoxifies, nourishes yin and moistens dryness, astringes and promotes tissue regeneration, clears the heart and relieves restlessness.

[0026] Licorice: sweet in taste and neutral in nature, it enters the heart, lung, spleen, and stomach meridians, nourishes the spleen and replenishes qi, clears away heat and detoxifies, eliminates phlegm and relieves cough, relieves acute pain, and harmonizes various medicines.

[0027] Astragalus: sweet and slightly warm in taste, it enters the lung, spleen, liver, and kidney meridians, replenishes qi and strengthens the exterior, restrains sweat and prevents loss of body fluids, supports sores and promotes tissue regeneration, and promotes diuresis and reduces swelling.

[0028] Stephania tetrandra: bitter, pungent and cold in nature, it enters the bladder, kidney, spleen and lung meridians, and is diuretic, reduces swelling, eliminates rheumatism and relieves pain.

[0029] Ginseng: sweet and slightly bitter, slightly warm, enters the heart, lung, spleen, and kidney meridians, greatly replenishes vital energy, nourishes the spleen and lungs, promotes the production of body fluids and blood, calms the mind and improves intelligence.

[0030] Bupleurum: bitter, pungent and slightly cold in taste, enters the Liver and Gallbladder Channels, harmonizes the exterior and interior, relieves liver depression, and raises yang and lifts the sunken.

[0031] Citrus aurantium: bitter, pungent and slightly cold in taste, enters the spleen and stomach meridians, regulates qi, relieves fullness, relieves stagnation and reduces bloating.

[0032] Platycodon grandiflorum: bitter and pungent in taste, neutral in nature, enters the lung meridian, clears the lungs and eliminates phlegm, relieves sore throat and discharges pus.

[0033] Peppermint: spicy and cool in nature, it enters the lung and liver meridians, dispels wind-heat, clears the head and eyes, relieves sore throat and rashes, and soothes the liver and promotes qi circulation.

[0034] Borneol: It tastes bitter and slightly cold in nature. It enters the heart, spleen and lung meridians. It can open the orifices, refresh the mind, clear away heat and relieve pain.

[0035] The compound Chinese medicine composition of the present invention targets the etiology and pathogenesis of stroke-related lung infection, drawing upon and modifying the principles of ancient formulas such as Ma Xing Shi Gan Tang, Ren Shen Baidu San, and Fang Ji Huang Qi Tang. After a stroke, patients experience mental disorder and dysfunction in regulating vital activities, directly impacting the lung's respiratory and phlegm-regulating functions. This, combined with insufficient vital energy and / or aspiration, can lead to lung infection. Patients with such stroke-related lung infection often present with a syndrome characterized by phlegm-heat congesting the lungs, characterized by common symptoms including: gurgling phlegm in the throat, chest tightness and shortness of breath, fever and sweating, nasal flaring and thirst, dark yellow urine, dry stool, a red tongue with a yellow coating, and a thready or thin, rapid pulse. The compound Chinese medicine composition of the present invention modifies and modifyes these three ancient formulas to achieve the effects of invigorating qi, strengthening the lungs, resolving phlegm, relieving asthma and promoting diuresis, and clearing the orifices and invigorating the mind. The main herbs in the prescription are raw astragalus and ginseng. Patients with stroke complicated by lung infection are in coma and have weak vital energy. If they lie in bed for a long time, they will be unable to expel the pathogenic factors from the exterior. Raw astragalus and ginseng are used together to replenish vital energy and consolidate the body, strengthen the vital energy and relieve the exterior symptoms. The auxiliary herbs are ephedra, raw gypsum, apricot kernel, bupleurum and stephania tetrandra. Patients have phlegm-heat blocking the lungs and phlegm-ringing in the throat. Ephedra and raw gypsum are based on the principle of Ma Xing Shi Gan Tang, which is used to treat both cold and hot symptoms, and to remove the properties and retain the effects. They can promote lung qi without adding heat, and clear lung heat without cooling it down, thus exerting the functions of promoting lung qi, relieving asthma, clearing heat and relieving restlessness. Apricot kernel tastes bitter and mainly descends, and is used together with ephedra to promote qi and descend, relieve asthma, and regulate the water channels. Bupleurum belongs to the Shaoyang meridian and can relieve the pathogenic factors that are half exterior and half interior. The patient's vital energy is weak, the condition recurs, and the disease progresses and retreats. Bupleurum can promote the evil to reach the surface, and can also expand the chest and regulate qi, regulate qi movement, Fangji is good at dispelling wind and dampness, and complements the function of Huangqi to invigorate qi and consolidate the surface. The two are the classic combination in Fangji Huangqi Decoction; the adjuvants in the prescription: Zhi Ke and Platycodon, Platycodon can promote lung qi and eliminate phlegm, relieve throat and discharge pus, Zhi Ke can regulate qi and relieve fullness, the two assist the monarch and minister drugs to promote lung qi and regulate qi movement; the messenger drugs in the prescription: mint, borneol, and roasted licorice. Mint and borneol have a fragrant smell, and can enhance the function of clearing heat, opening the orifices and refreshing the mind in the spray form. Roasted licorice is an old Chinese medicine, which harmonizes the various drugs so that the effects of each drug in the prescription can be coordinated.

[0036] Due to the adoption of the above technical solution, the present invention has the following advantages and beneficial effects:

[0037] The present invention addresses the shortcomings and drawbacks of existing Western medicine for treating cerebral hemorrhage complicated by pulmonary infection, such as limited means and efficacy, and the development of drug resistance in patients with long-term use of antibiotics. The use of the compound Chinese medicine composition of the present invention can enhance efficacy, reduce the use of antibiotics, and reduce the development of drug resistance. Furthermore, the compound Chinese medicine composition of the present invention can be formulated as a spray, which is easier to use than traditional decoctions for oral administration, requires less liquid, avoids gastrointestinal reactions and vomiting, and reduces the risk of secondary aspiration. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 Schematic diagram of lung CT comparison before and after treatment of the patient in Example 7.

[0039] Figure 2 Schematic diagram of lung CT comparison before and after treatment of the patient in Example 8.

[0040] Figure 3 Schematic diagram of lung CT comparison before and after treatment of the patient in Example 9. DETAILED DESCRIPTION

[0041] In order to explain the present invention more clearly, the present invention is further described below in conjunction with preferred embodiments. Those skilled in the art should understand that the following specific description is illustrative rather than restrictive and should not be used to limit the scope of protection of the present invention.

[0042] Example 1

[0043] A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components by weight:

[0044] Ephedra 60g, gypsum 90g, almond 30g, raw astragalus 150g, Stephania tetrandra 100g, ginseng 120g, bupleurum 60g, fructus aurantii 40g, platycodon 20g, roasted licorice 150g, mint 80g, borneol 3g.

[0045] A method for preparing a spray comprises the following steps:

[0046] Weigh each component according to the above mass, crush ephedra, apricot kernel, raw astragalus, stephania tetrandra, ginseng, bupleurum, fructus aurantii, and platycodon grandiflorum into granules respectively, pass through a 20-mesh sieve, and reflux extract with 75% ethanol three times, adding 8 times the amount of 75% ethanol each time, and extract for 1.5 hours. After filtering, the medicinal liquids are combined and concentrated at 40°C to a relative density of 1.03-1.05 to obtain 60 mL of a mixture concentrate.

[0047] Gypsum was crushed into fine powder, passed through a 100-mesh sieve, added with 10 times the amount of water and boiled for 1 hour, filtered, and concentrated at 40°C to a relative density of 1.05-1.07 to obtain 90 mL of gypsum concentrate.

[0048] The prepared licorice root was crushed into granules, passed through a 10-mesh sieve, added with 15 times the amount of water and boiled for 1.5 hours, filtered, and the residue was added with 10 times the amount of water and boiled for 1 hour, filtered, and the combined medicinal liquids were concentrated at a temperature of 40°C to a relative density of 1.03-1.04 to obtain 150 mL of prepared licorice root concentrate.

[0049] Extract volatile oil from mint using steam distillation: Cut the mint into 5-10 cm segments, place in a round-bottom flask, add 500 mL of purified water, and soak for 30 minutes. Connect a distillation apparatus, turn on the condenser water, flow rate 2 L / min, heat to boiling (100°C), and control the distillation rate to 2-3 mL / min. Collect the distillate into a volatile oil receiver until the oil-water separation layer no longer increases. Let it stand for 1 hour until the oil and water are completely separated. Carefully aspirate the upper volatile oil with a micropipette and transfer it to a brown glass bottle to obtain 1.6 mL of mint volatile oil. Concentrate the remaining liquid to 40 mL to obtain the remaining mint concentrate.

[0050] Borneol was dissolved in 30 mL of ethanol and filtered to obtain about 30 mL of borneol ethanol solution.

[0051] 60 mL of the mixture concentrate, 90 mL of the raw gypsum concentrate, 150 mL of the roasted licorice concentrate, and 40 mL of the remaining mint concentrate were combined, and the pH was adjusted to 4.5 by titration with 1 mol / L HCl. 5% gelatin solution was added until no more precipitation was formed. Purified water was added to the mixed concentrate. The volume-to-mass ratio of the mixed concentrate after adding purified water to the total mass of the medicinal materials (referring to the total mass of ephedra, raw gypsum, apricot kernel, raw astragalus, tetrandra, ginseng, bupleurum, fructus aurantii, platycodon, roasted licorice, mint, and borneol) was 1:1, to obtain approximately 900 mL of solution. Approximately 4800 mL of 95% ethanol was added for alcohol precipitation. The solution was allowed to stand at 5°C for 18 hours and filtered to obtain 5500 mL of clear filtrate. Part of the ethanol was recovered by rotary evaporation at 40°C and concentrated to obtain 1000 mL of the combined medicinal solution.

[0052] To 100 mL of a 20% aqueous solution of paloxamer, 1.6 mL of peppermint essential oil and 30 mL of borneol ethanol solution were added while stirring, and the mixture was thoroughly mixed. 1000 mL of the combined solution was added and stirred. The pH was adjusted to 7.0 by titration with 1 mol / L sodium hydroxide solution. The volume was adjusted to 2000 mL by adding purified water, and the mixture was sterilized through a 0.22 µm filter to obtain a compound Chinese medicine mixture. The compound Chinese medicine mixture and the propellant, hydrofluoroalkane HFA-134a, were aseptically filled into aerosol containers using pressure-filling equipment, with each container containing 20 mL of the compound Chinese medicine mixture and 80 g of the propellant, resulting in a total of 100 containers.

[0053] Example 2

[0054] A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components by weight:

[0055] Ephedra 45g, gypsum 100g, almond 40g, raw astragalus 180g, Stephania tetrandra 100g, ginseng 120g, bupleurum 60g, fructus aurantii 50g, platycodon 30g, roasted licorice 150g, mint 60g, borneol 3g.

[0056] A method for preparing a spray comprises the following steps:

[0057] Weigh each component according to the above mass, grind ephedra, apricot kernel, raw astragalus, stephania tetrandra, ginseng, bupleurum, fructus aurantii, and platycodon grandiflorum into granules respectively, pass through a 20-mesh sieve, and reflux extract with 75% ethanol three times, adding 8 times the amount of 75% ethanol each time, and extract for 1.5 hours. After filtering, the medicinal liquids are combined and concentrated at 40°C to a relative density of 1.03-1.05 to obtain 70 mL of a mixture concentrate.

[0058] Gypsum was crushed into fine powder, passed through a 100-mesh sieve, added with 10 times the amount of water and boiled for 1 hour, filtered, and concentrated at 40°C to a relative density of 1.05-1.07 to obtain 100 mL of gypsum concentrate.

[0059] The prepared licorice root was crushed into granules, passed through a 10-mesh sieve, added with 15 times the amount of water and boiled for 1.5 hours, filtered, and the residue was added with 10 times the amount of water and boiled for 1 hour, filtered, and the combined medicinal liquids were concentrated at a temperature of 40°C to a relative density of 1.03-1.04 to obtain 150 mL of prepared licorice root concentrate.

[0060] Extract volatile oil from mint using steam distillation: Cut the mint into 5-10 cm segments, place in a round-bottom flask, add 500 mL of purified water, and soak for 30 minutes. Connect a distillation apparatus, turn on the condenser water, flow rate 2 L / min, heat to boiling (100°C), and control the distillation rate to 2-3 mL / min. Collect the distillate into a volatile oil receiver until the oil-water separation layer no longer increases. Let it stand for 1 hour until the oil and water are completely separated. Carefully aspirate the upper volatile oil with a micropipette and transfer it to a brown glass bottle to obtain 1.2 mL of mint volatile oil. Concentrate the remaining liquid to 40 mL to obtain the remaining mint concentrate.

[0061] Borneol was dissolved in 30 mL of ethanol and filtered to obtain about 30 mL of borneol ethanol solution.

[0062] Combine 70 mL of the mixture concentrate, 100 mL of gypsum concentrate, 150 mL of roasted licorice concentrate, and 40 mL of the remaining mint concentrate, adjust the pH to 4.5 by titration with 1 mol / L HCl, add 5% gelatin solution until no more precipitate is generated, add purified water to the mixed concentrate, and the volume-to-mass ratio of the mixed concentrate after adding purified water to the total mass of the medicinal materials is 1:1 to obtain about 980 mL of solution, add about 5200 mL of 95% ethanol for alcohol precipitation, let stand at 5°C for 18 hours, filter to obtain 6100 mL of clear filtrate, recover part of the ethanol by rotary evaporator at 40°C, concentrate to obtain 1100 mL of the combined medicinal solution.

[0063] To 110 mL of a 20% aqueous solution of paloxam, 1.2 mL of peppermint essential oil and 30 mL of borneol ethanol solution were added while stirring, and the mixture was thoroughly mixed. 1100 mL of the combined solution was added and stirred. The pH was adjusted to 7.0 by titration with 1 mol / L sodium hydroxide solution. The volume was adjusted to 2200 mL by adding purified water, and the mixture was sterilized through a 0.22 µm filter to obtain a compound Chinese medicine mixture. The compound Chinese medicine mixture and the propellant, hydrofluoroalkane HFA-134a, were aseptically filled into aerosol containers using pressure-filling equipment, with each container containing 20 mL of the compound Chinese medicine mixture and 80 g of the propellant, resulting in a total of 110 containers.

[0064] Example 3

[0065] A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components by weight:

[0066] Ephedra 30g, gypsum 120g, almond 50g, raw astragalus 180g, Stephania tetrandra 120g, ginseng 90g, bupleurum 80g, fructus aurantii 60g, platycodon 40g, roasted licorice 180g, mint 45g, borneol 4g.

[0067] A method for preparing a spray comprises the following steps:

[0068] Weigh each component according to the above mass, crush ephedra, apricot kernel, raw astragalus, stephania tetrandra, ginseng, bupleurum, fructus aurantii, and platycodon grandiflorum into granules, pass through a 20-mesh sieve, and reflux extract with 75% ethanol three times, adding 8 times the amount of 75% ethanol each time, and extract for 1.5 hours. After filtering, the medicinal liquids are combined and concentrated at 40°C to a relative density of 1.03-1.05 to obtain 80 mL of a mixture concentrate.

[0069] Gypsum was crushed into fine powder, passed through a 100-mesh sieve, added with 10 times the amount of water and boiled for 1 hour, filtered, and concentrated at 40°C to a relative density of 1.05-1.07 to obtain 120 mL of gypsum concentrate.

[0070] The prepared licorice root was crushed into granules, passed through a 10-mesh sieve, added with 15 times the amount of water and boiled for 1.5 hours, filtered, and the residue was added with 10 times the amount of water and boiled for 1 hour, filtered, and the combined medicinal liquids were concentrated at a temperature of 40°C to a relative density of 1.03-1.04 to obtain 180 mL of prepared licorice root concentrate.

[0071] Extract volatile oil from mint using steam distillation: Cut the mint into 5-10 cm segments, place in a round-bottom flask, add 500 mL of purified water, and soak for 30 minutes. Connect a distillation apparatus, turn on the condenser water, flow rate 2 L / min, heat to boiling (100°C), and control the distillation rate to 2-3 mL / min. Collect the distillate into a volatile oil receiver until the oil-water separation layer no longer increases. Let it stand for 1 hour until the oil and water are completely separated. Carefully aspirate the upper volatile oil with a micropipette and transfer it to a brown glass bottle to obtain 1.0 mL of mint volatile oil. Concentrate the remaining liquid to 30 mL to obtain the remaining mint concentrate.

[0072] Borneol was dissolved in 40 mL of ethanol and filtered to obtain about 40 mL of borneol ethanol solution.

[0073] Combine 80 mL of the mixture concentrate, 120 mL of gypsum concentrate, 180 mL of roasted licorice concentrate, and 30 mL of the remaining mint concentrate, adjust the pH to 4.5 by titration with 1 mol / L HCl, add 5% gelatin solution until no more precipitate is generated, add purified water to the mixed concentrate, and the volume-to-mass ratio of the mixed concentrate after adding purified water to the total mass of the medicinal materials is 1:1 to obtain about 1040 mL of solution, add about 5800 mL of 95% ethanol for alcohol precipitation, let stand at 5°C for 18 hours, filter to obtain 6600 mL of clear filtrate, recover part of the ethanol by rotary evaporator at 40°C, concentrate to obtain 1200 mL of the combined medicinal solution.

[0074] To 150 mL of a 20% aqueous solution of paloxamer, 1.0 mL of peppermint essential oil and 30 mL of borneol ethanol solution were added while stirring, and the mixture was thoroughly mixed. 1200 mL of the combined solution was added and stirred thoroughly. The pH was adjusted to 7.0 by titration with 1 mol / L sodium hydroxide solution. The volume was adjusted to 2500 mL by adding purified water, and the mixture was sterilized through a 0.22 µm filter to obtain a compound Chinese medicine mixture. The compound Chinese medicine mixture and the propellant, hydrofluoroalkane HFA-134a, were aseptically filled into aerosol containers using pressure-filling equipment, with each container containing 20 mL of the compound Chinese medicine mixture and 80 g of the propellant, resulting in a total of 125 containers.

[0075] Example 4

[0076] A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components by weight:

[0077] Ephedra 45g, gypsum 105g, apricot kernel 40g, raw astragalus 165g, Stephania tetrandra 110g, ginseng 105g, bupleurum 70g, fructus aurantii 50g, platycodon 30g, roasted licorice 165g, mint 65g, borneol 3.5g.

[0078] A method for preparing a spray comprises the following steps:

[0079] Weigh each component according to the above mass, grind ephedra, apricot kernel, raw astragalus, stephania tetrandra, ginseng, bupleurum, fructus aurantii, and platycodon grandiflorum into granules respectively, pass through a 20-mesh sieve, and reflux extract with 75% ethanol three times, adding 8 times the amount of 75% ethanol each time, and extract for 1.5 hours. After filtering, the medicinal liquids are combined and concentrated at 40°C to a relative density of 1.03-1.05 to obtain 70 mL of a mixture concentrate.

[0080] Gypsum was crushed into fine powder, passed through a 100-mesh sieve, added with 10 times the amount of water and boiled for 1 hour, filtered, and concentrated at 40°C to a relative density of 1.05-1.07 to obtain 105 mL of gypsum concentrate.

[0081] The prepared licorice root was crushed into granules, passed through a 10-mesh sieve, added with 15 times the amount of water and boiled for 1.5 hours, filtered, and the residue was added with 10 times the amount of water and boiled for 1 hour, filtered, and the combined medicinal liquids were concentrated at a temperature of 40°C to a relative density of 1.03-1.04 to obtain 165 mL of prepared licorice root concentrate.

[0082] Extract volatile oil from mint using steam distillation: Cut the mint into 5-10 cm segments, place in a round-bottom flask, add 500 mL of purified water, and soak for 30 minutes. Connect a distillation apparatus, turn on the condenser water, flow rate 2 L / min, heat to boiling (100°C), and control the distillation rate to 2-3 mL / min. Collect the distillate into a volatile oil receiver until the oil-water separation layer no longer increases. Let it stand for 1 hour until the oil and water are completely separated. Carefully aspirate the upper volatile oil with a micropipette and transfer it to a brown glass bottle to obtain 1.3 mL of mint volatile oil. Concentrate the remaining liquid to 35 mL to obtain the remaining mint concentrate.

[0083] Borneol was dissolved in 35 mL of ethanol and filtered to obtain about 35 mL of borneol ethanol solution.

[0084] Combine 70 mL of the mixture concentrate, 105 mL of gypsum concentrate, 165 mL of roasted licorice concentrate, and 35 mL of the remaining mint concentrate, adjust the pH to 4.5 by titration with 1 mol / L HCl, add 5% gelatin solution until no more precipitate is generated, add purified water to the mixed concentrate, and the volume-to-mass ratio of the mixed concentrate after adding purified water to the total mass of the medicinal materials is 1:1 to obtain about 950 mL of solution, add about 5100 mL of 95% ethanol for alcohol precipitation, let stand at 5°C for 18 hours, filter to obtain 6000 mL of clear filtrate, recover part of the ethanol by rotary evaporator at 40°C, concentrate to obtain 1100 mL of the combined medicinal solution.

[0085] To 120 mL of a 20% aqueous solution of paloxam, 1.3 mL of peppermint essential oil and 35 mL of borneol ethanol solution were added while stirring, and the mixture was thoroughly mixed. 1100 mL of the combined solution was added and stirred. The pH was adjusted to 7.0 by titration with 1 mol / L sodium hydroxide solution. The volume was adjusted to 2200 mL by adding purified water, and the mixture was sterilized through a 0.22 µm filter to obtain a compound Chinese medicine mixture. The compound Chinese medicine mixture and the propellant, hydrofluoroalkane HFA-134a, were aseptically filled into aerosol containers using pressure-filling equipment, with each container containing 20 mL of the compound Chinese medicine mixture and 80 g of the propellant, resulting in a total of 110 containers.

[0086] Example 5

[0087] A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components by weight:

[0088] Ephedra 50g, gypsum 110g, apricot kernel 45g, raw astragalus 170g, Stephania tetrandra 105g, ginseng 100g, bupleurum 65g, fructus aurantii 45g, platycodon 35g, roasted licorice 170g, mint 55g, borneol 3g.

[0089] A method for preparing a spray comprises the following steps:

[0090] Weigh each component according to the above mass, crush ephedra, apricot kernel, raw astragalus, stephania tetrandra, ginseng, bupleurum, fructus aurantii, and platycodon grandiflorum into granules respectively, pass through a 20-mesh sieve, and reflux extract with 75% ethanol three times, adding 8 times the amount of 75% ethanol each time, and extract for 1.5 hours. After filtering, the medicinal liquids are combined and concentrated at 40°C to a relative density of 1.03-1.05 to obtain 75 mL of a mixture concentrate.

[0091] Gypsum was crushed into fine powder, passed through a 100-mesh sieve, added with 10 times the amount of water and boiled for 1 hour, filtered, and concentrated at 40°C to a relative density of 1.05-1.07 to obtain 110 mL of gypsum concentrate.

[0092] The prepared licorice root was crushed into granules, passed through a 10-mesh sieve, added with 15 times the amount of water and boiled for 1.5 hours, filtered, and the residue was added with 10 times the amount of water and boiled for 1 hour, filtered, and the medicinal liquid was combined and concentrated to a relative density of 1.03-1.04 at 40°C to obtain 170 mL of prepared licorice root concentrate.

[0093] Extract volatile oil from mint using steam distillation: Cut the mint into 5-10 cm segments, place in a round-bottom flask, add 500 mL of purified water, and soak for 30 minutes. Connect a distillation apparatus, turn on the condenser water, flow rate 2 L / min, heat to boiling (100°C), and control the distillation rate to 2-3 mL / min. Collect the distillate into a volatile oil receiver until the oil-water separation layer no longer increases. Let it stand for 1 hour until the oil and water are completely separated. Carefully aspirate the upper volatile oil with a micropipette and transfer it to a brown glass bottle to obtain 1.1 mL of mint volatile oil. Concentrate the remaining liquid to 40 mL to obtain the remaining mint concentrate.

[0094] Borneol was dissolved in 30 mL of ethanol and filtered to obtain about 30 mL of borneol ethanol solution.

[0095] Combine 75 mL of the mixture concentrate, 110 mL of gypsum concentrate, 170 mL of roasted licorice concentrate, and 40 mL of the remaining mint concentrate, adjust the pH to 4.5 by titration with 1 mol / L HCl, add 5% gelatin solution until no more precipitate is generated, add purified water to the mixed concentrate, and the volume-to-mass ratio of the mixed concentrate after adding purified water to the total mass of the medicinal materials is 1:1 to obtain about 1000 mL of solution, add about 5300 mL of 95% ethanol for alcohol precipitation, let stand at 5°C for 18 hours, filter to obtain 6200 mL of clear filtrate, recover part of the ethanol by rotary evaporator at 40°C, concentrate to obtain 1150 mL of the combined medicinal solution.

[0096] To 115 mL of a 20% aqueous solution of paloxam, 1.1 mL of peppermint essential oil and 30 mL of borneol ethanol solution were added while stirring, and the mixture was thoroughly mixed. 1150 mL of the combined solution was added and stirred. The pH was adjusted to 7.0 by titration with 1 mol / L sodium hydroxide solution. The volume was adjusted to 2300 mL by adding purified water, and the mixture was sterilized through a 0.22 µm filter to obtain a compound Chinese medicine mixture. The compound Chinese medicine mixture and the propellant, hydrofluoroalkane HFA-134a, were aseptically filled into aerosol containers using pressure-filling equipment, with each container containing 20 mL of the compound Chinese medicine mixture and 80 g of the propellant. A total of 115 containers were prepared.

[0097] Example 6

[0098] Clinical validation

[0099] 1.1 General Information

[0100] The present invention recruited a total of 84 subjects with cerebral hemorrhage complicated by lung infection from the hospital and randomly divided them into two groups (control group and experimental group), with 42 cases in each group. The general data of the two groups were tested for normality and were both normally or approximately normally distributed. There was no statistically significant difference in gender composition and age between the two groups of subjects. In summary, the general data of the two groups of subjects in the present invention were basically balanced and comparable.

[0101] 1.2 Diagnostic criteria

[0102] Western medicine diagnostic standards: The diagnosis of cerebral hemorrhage is formulated in reference to the 2023 "Guidelines for the Clinical Management of Cerebrovascular Diseases in China"; the diagnosis of lung infection refers to the clinical diagnostic criteria for stroke-related pneumonia in the 2019 "Chinese Expert Consensus on the Diagnosis and Treatment of Stroke-Related Pneumonia".

[0103] TCM diagnostic criteria: Refer to the TCM Disease Diagnosis and Efficacy Criteria, which conforms to the TCM pathogenesis of wind-heat evil obstructing the lungs and weak vital energy. Symptoms include phlegm in the throat, chest tightness and shortness of breath, fever and sweating, nasal flaring and thirst, yellow and dark urine, dry stool, red tongue with yellow coating, and thin and rapid pulse or thin and rapid pulse.

[0104] 1.3 Inclusion criteria

[0105] (1) Meet the above-mentioned diagnostic criteria of traditional Chinese medicine and Western medicine; (2) Have stable condition; (3) Be aged 40-70 years, regardless of gender; (4) Voluntarily participate in the study and sign the informed consent form.

[0106] 1.4 Exclusion criteria

[0107] (1) Secondary cerebral hemorrhage, signs of infection or fever upon admission, craniocerebral trauma, space-occupying lesions, or other critical illnesses;

[0108] (2) had received antibiotics or glucocorticoids 2 weeks before admission;

[0109] (3) Postoperative deep coma, impaired consciousness, mental disorder, or unstable vital signs;

[0110] (4) Allergic constitution;

[0111] (5) Combined infection at multiple sites.

[0112] 1.5 Treatment

[0113] The control group received conventional treatment, including antitussive, expectorant, anti-infection and intracranial pressure reduction. The experimental group was given the spray prepared in Example 1 of the present invention in addition to the control group, and the patient pressed the product directly into the mouth when inhaling, 3 times a day, 3-5 times each time.

[0114] The observation period for both groups was 14 days.

[0115] 1.6 Observation indicators

[0116] 1.6.1 Evaluation of the efficacy of traditional Chinese medicine

[0117] Refer to the Principles for Clinical Guidance of New Chinese Medicines for specific efficacy criteria: (1) Significantly effective: TCM syndrome score reduced by >70%. (2) Effective: TCM syndrome score reduced by 30%-70%. (3) Ineffective: TCM syndrome score reduced by <30%.

[0118] 1.6.2 Inflammatory markers

[0119] Before and after treatment, 2-4 ml of cubital venous blood samples were drawn and placed in vacuum tubes. The samples were centrifuged, and the upper serum layer was collected for analysis. The samples were then assayed using an enzyme-linked immunosorbent assay (ELISA) for interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein levels.

[0120] 1.7 Statistical Description

[0121] Data were analyzed using IBM SPSS 26.0 software. Data organized in Excel were imported into IBM SPSS 26.0 for statistical analysis. Baseline data were processed as follows: When measurement data followed a normal or nearly normal distribution with homogeneous variances, they were expressed as mean ± standard deviation. Intergroup comparisons were performed using the independent sample t-test. If data did not conform to a normal distribution, they were presented as medians and interquartile ranges [M(P25, P75)], and intergroup comparisons were performed using the Wilcoxon rank-sum test. For binary or multi-categorical unordered data, count data were presented using frequency, rate, and component ratio statistics, using the chi-square test. For ordered data, the nonparametric Wilcoxon rank-sum test was used.

[0122] 1.8 Results

[0123] 1.8.1 The results of TCM efficacy evaluation are shown in Table 1. The effective rate of the experimental group was 88.1%, and the effective rate of the control group was 69.0%, with statistically significant differences (P < 0.05).

[0124] Table 1 Clinical efficacy of the two groups

[0125]

[0126] 1.8.2 Inflammatory Indicators As shown in Table 2, there were no statistically significant differences in interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), and high-sensitivity C-reactive protein (Hs-CRP) between the control and experimental groups before treatment, and the baseline levels were comparable. After treatment, the mean decreases in interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein in the experimental group were significantly greater than those in the control group, and the differences were statistically significant (P < 0.05).

[0127] Table 2 Serum inflammatory indicators in the two groups before and after treatment

[0128]

[0129] 1.9 Discussion of Efficacy Evaluation

[0130] The effective rate of the experimental group was 88.1%, and the effective rate of the control group was 69.0%, indicating that both conventional treatment and conventional treatment combined with the spray prepared in Example 1 of the present invention can achieve clinical results, and the difference between the two is statistically significant, proving that conventional treatment combined with the spray prepared in Example 1 of the present invention is superior to conventional treatment alone. After treatment, interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein decreased in both the control and experimental groups, with statistically significant differences. This indicates that both conventional treatment combined with the spray prepared in Example 1 of the present invention and conventional treatment alone can reduce the inflammation of cerebral hemorrhage complicated by lung infection, and the mean decrease in interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein in the experimental group was higher than the mean decrease in the control group, with statistically significant differences. This indicates that conventional treatment combined with the spray prepared in Example 1 of the present invention is superior to conventional treatment in improving inflammatory indicators such as interleukin-6, tumor necrosis factor-α, and high-sensitivity C-reactive protein.

[0131] Example 7

[0132] Patient Liu, male, 70 years old, was admitted to the emergency department due to "sudden loss of consciousness for 2 hours". Western medicine diagnosed it as hypertensive cerebral hemorrhage. After hematoma evacuation in neurosurgery, he was transferred to the internal medicine department for further diagnosis and treatment. His condition improved further. After resuming a semi-liquid diet, he developed high fever, cough and sputum a few days later due to choking. Blood routine: WBC 12.5×10 9 / L↑, N% 83%↑, CRP 87mg / L (↑). PCT: 2.3ng / ml (↑). Lung CT scan showed inflammation in the right middle and left lower lobes, with localized consolidation. Please refer to clinical data for follow-up examination after treatment. Diagnosed with lung infection, suspected to be caused by coughing and choking on food, the patient was fasted, a gastric tube was placed, and conventional treatment was administered with the spray prepared in Example 2. The patient was instructed to apply the spray directly to the mouth while inhaling, three times daily, 3-5 times each time. Symptoms improved significantly after three days and were essentially resolved after five days. A follow-up lung CT scan one week after discharge showed increased markings in both lungs. Please refer to clinical data for follow-up examination. Figure 1 2 is a schematic diagram comparing lung CT images of a patient in Example 7 before and after treatment, wherein the left figure is a schematic diagram of lung CT images before treatment with the spray prepared in Example 2 of the present invention, and the right figure is a schematic diagram of lung CT images after treatment with the spray prepared in Example 2 of the present invention.

[0133] Example 8

[0134] The patient, Zhao Moumou, female, 53 years old, was admitted to the emergency department due to "sudden headache accompanied by numbness of the right limbs for 2 hours". Western medicine diagnosed it as hypertensive cerebral hemorrhage. After symptomatic treatment and stable condition, she was transferred to the ward for further treatment. The patient's Kubota water drinking test was level 4, and a nasogastric tube was placed. After being bedridden for 10 days, she developed cough and sputum, and her body temperature rose to 38.5℃. The blood routine showed: WBC 15.2×10 9 / L↑, N% 89%↑, CRP 120mg / L (↑). PCT: 2.5ng / ml (↑). Lung CT scan showed bilateral pneumonia, micronodules in the left lower lobe, and calcifications in the left lower lobe. Diagnosed with lung infection, symptomatic treatment was administered with the spray prepared in Example 2, with the patient instructed to apply 3-5 depresses directly into the mouth during inhalation, three times daily. Symptoms resolved after one week, and blood counts returned normal. A follow-up lung CT scan more than two weeks later showed inflammation in the left and right lower lobes, with partial absorption of contrast compared to the previous CT scan. Please consider clinical and follow-up examinations. Micronodules in the left lung and small calcifications in the right lower lobe. Figure 2 3 is a schematic diagram comparing lung CT images of a patient in Example 8 before and after treatment, wherein the left figure is a schematic diagram of lung CT images before treatment with the spray prepared in Example 2 of the present invention, and the right figure is a schematic diagram of lung CT images after treatment with the spray prepared in Example 2 of the present invention.

[0135] Example 9

[0136] Patient Gao, male, 81 years old, was admitted to the emergency department due to "sudden loss of consciousness for 3 hours". Western medicine diagnosed it as hypertensive cerebral hemorrhage and gave conservative treatment. He was bedridden in the ward for a long time, was drowsy, answered questions irrelevantly, had incontinence, and had an indwelling gastric tube and a urinary catheter. A few days later, he developed fever, cough, wheezing, phlegm in the throat, and obvious moist rales on auscultation of the right lung. Blood routine test showed: WBC 10.3×10 9 / L↑, N% 78%↑, CRP 95mg / L (↑). PCT: 2.2ng / ml (↑). Lung CT scan showed infection in the right lower lobe. Follow-up examination is recommended. A small nodule in the right oblique fissure is under investigation. Diagnosed with lung infection, the patient was incontinent and had previously taken traditional Chinese medicine decoctions, which resulted in frequent diarrhea and difficulty in nursing. For this lung infection, conventional treatment was administered with the spray prepared in Example 2. The patient was instructed to apply the spray directly to the mouth while inhaling, three times daily, 3-5 times each time. Symptoms significantly improved after one week. A follow-up lung CT scan two weeks later showed right pneumonia and partial lung consolidation. Please review the patient based on clinical findings and post-treatment results. Figure 3 1 is a schematic diagram comparing lung CT images of a patient in Example 9 before and after treatment, wherein the left figure is a schematic diagram of lung CT images before treatment with the spray prepared in Example 2 of the present invention, and the right figure is a schematic diagram of lung CT images after treatment with the spray prepared in Example 2 of the present invention.

[0137] The above description is merely a preferred embodiment of the present invention and does not constitute any form of limitation to the present invention. Although the present invention has been disclosed as above in terms of a preferred embodiment, it is not intended to limit the present invention. Any technician familiar with the present invention can make slight changes or modifications to equivalent embodiments using the above-mentioned technical contents without departing from the scope of the technical solution of the present invention. However, any simple modifications, equivalent changes and modifications made to the above embodiments based on the technical essence of the present invention without departing from the content of the technical solution of the present invention are still within the scope of the solution of the present invention.

Claims

1. A compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection, characterized in that: It is made of the following components in parts by weight: 30-60 parts of ephedra, 90-120 parts of gypsum, 30-50 parts of apricot kernel, 150-180 parts of raw astragalus, 100-120 parts of tetrandra, 90-120 parts of ginseng, 60-80 parts of bupleurum, 40-60 parts of fructus aurantii, 20-40 parts of platycodon, 150-180 parts of roasted liquorice, 45-80 parts of mint, and 3-4 parts of borneol.

2. The compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection according to claim 1, characterized in that: The compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight: 60 parts of Ephedra, 90 parts of Gypsum, 30 parts of Apricot Kernel, 150 parts of Astragalus, 100 parts of Stephania Tetrandra, 120 parts of Ginseng, 60 parts of Bupleurum, 40 parts of Fructus Aurantii Immaturus, 20 parts of Platycodon, 150 parts of Radix Glycyrrhizae Preparata, 80 parts of Menthol, and 3 parts of Borneolum Syntheticum.

3. The compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection according to claim 1, characterized in that: The compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight: 45 parts of ephedra, 100 parts of gypsum, 40 parts of apricot kernel, 180 parts of raw astragalus, 100 parts of tetrandra, 120 parts of ginseng, 60 parts of bupleurum, 50 parts of fructus aurantii, 30 parts of platycodon, 150 parts of roasted liquorice, 60 parts of mint, and 3 parts of borneol.

4. The compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection according to claim 1, characterized in that: The compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight: 30 parts of ephedra, 120 parts of gypsum, 50 parts of apricot kernel, 180 parts of raw astragalus, 120 parts of tetrandra, 90 parts of ginseng, 80 parts of bupleurum, 60 parts of fructus aurantii, 40 parts of platycodon, 180 parts of roasted liquorice, 45 parts of mint, 4 parts of borneol.

5. The compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection according to claim 1, characterized in that: The compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight: 45 parts of ephedra, 105 parts of gypsum, 40 parts of apricot kernel, 165 parts of raw astragalus, 110 parts of tetrandra, 105 parts of ginseng, 70 parts of bupleurum, 50 parts of fructus aurantii, 30 parts of platycodon, 165 parts of roasted liquorice, 65 parts of mint, and 3.5 parts of borneol.

6. The compound Chinese medicine composition for assisting the treatment of cerebral hemorrhage complicated with pulmonary infection according to claim 1, characterized in that: The compound Chinese medicine composition for auxiliary treatment of cerebral hemorrhage combined with pulmonary infection is prepared from the following components in parts by weight: 50 parts of ephedra, 110 parts of gypsum, 45 parts of apricot kernel, 170 parts of raw astragalus, 105 parts of tetrandra, 100 parts of ginseng, 65 parts of bupleurum, 45 parts of fructus aurantii, 35 parts of platycodon, 170 parts of roasted liquorice, 55 parts of mint, and 3 parts of borneol.

7. Use of the compound Chinese medicine composition according to any one of claims 1 to 6 in the preparation of a medicament for the auxiliary treatment of cerebral hemorrhage complicated with pulmonary infection.

8. A pharmaceutical preparation, characterized in that The compound Chinese medicine composition is prepared from the compound Chinese medicine composition according to any one of claims 1 to 6 and pharmaceutically acceptable excipients.

9. The pharmaceutical preparation according to claim 8, characterized in that The dosage form of the pharmaceutical preparation is selected from sprays, capsules, tablets, powders, granules, oral liquids, and pills.

10. Use of the pharmaceutical preparation according to claim 8 or 9 in preparing a drug for auxiliary treatment of cerebral hemorrhage complicated with pulmonary infection.

Images